Aavatar Therapeutics Inc.

Have updates for this profile? Please contribute data

= Subscriber Access Only

You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.

With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.

Aavatar Therapeutics Inc. - overview

Established

2020

Location

Hanam-si, Gyeonggido, South Korea

Primary Industry

Biotechnology

About

Founded in 2020 and based in Gyeonggi-do, South Korea, Aavatar Therapeutics Inc. operates as a biotechnology company that develops nanoparticle-based products as agents to treat genetic diseases. As of November 2023, the company is being led by its CEO, Seunghee Cho. In November 2023, Aavatar Therapeutics Inc.


raised KRW 5 billion in series A funding led by new investor T. S. Investment. Other new investors Smilegate Investment, Shinhan Capital, and WONIK Investment Partners also participated in the round.


The firm develops and offers a gene therapy platform based on artificial intelligence (AI) and deep learning that provides individual diagnoses based on their disease and offers gene therapy products created using nanoparticles to offer therapies. The company creates drugs using capsid engineering and promoter engineering technologies.


Current Investors

Smilegate Investment, Shinhan Capital, WONIK Investment Partners

Primary Industry

Biotechnology

Sub Industries

Molecular Science, Genetics & Gene Therapy

Website

https://www.aavatartps.com/

Verticals

Artificial Intelligence

Company Stage

Series A

Total Amount Raised

Subscriber access only

Aavatar Therapeutics Inc. - financials

Fiscal Year EndedDec 31, 2020Dec 31, 2021Dec 31, 2022
Revenue (USD)---
% Revenue Growth (YoY)---
EBITDA (USD)---
Operating Income (USD)---
Operating Margin---
% EBITDA Margin---
NET Income (USD)---
% Net Margin---
GoingPro

Time to go Pro

Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.